The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs.

Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early big tech rally faded and a ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Product Preview is a weekly series spotlighting the latest and greatest debuts in the marketplace. Check back every Friday ...